Lymph node involvement: Positive about the role of the recurrence score in estrogen-driven breast cancer?
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 30387877.
- Also identified by DOI 10.1002/cncr.31814 and PMC identifier 6329661.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
It remains unclear whether there is clinical utility for withholding chemotherapy in HR+/HER2-, node-positive breast cancer based upon the 21-gene Recurrence Score. While we await the results from randomized, phase III trials, this editorial addresses additional observational data that suggest there may be a role for this genomic assay in this patient population.
Medical subject headings
- Breast Neoplasms